|
}}
{{COVID-19 pandemic sidebar|expanded=medis}}
'''CoronaVac''' adalah [[vaksin COVIDCovid-19]] yang dikembangkan oleh perusahaan biofarmasi asal [[Tiongkok]], [[Sinovac Biotech|Sinovac]].<ref name="jakartaglobe">{{Cite web|date=August 11, 2020|title=Indonesia Starts CoronaVac Phase 3 Clinical Trials|url=https://jakartaglobe.id/news/indonesia-starts-coronavac-phase-3-clinical-trials|website=Jakarta Globe|archive-url=https://web.archive.org/web/20201013211900/https://jakartaglobe.id/news/indonesia-starts-coronavac-phase-3-clinical-trials|archive-date=October 13, 2020|access-date=2020-08-26|url-status=live}}</ref> Sejak pertengahan tahun 2020, calon vaksin ini menjalani [[Tahap-tahap penelitian klinis|penelitian klinis tahap III]],<ref name="NCname= nct04456595=">{{ClinicalTrialsGov|NCT04456595|Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)}}</ref><ref>{{Cite web|date=August 10, 2020|title=A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18-59 years in Indonesia|url=https://www.ina-registry.org/index.php?act=registry_trial_detail&code_trial=16202009080721WXFM0YX|website=PT Bio Farma|publisher=Registri Penyakit Indonesia|archive-url=https://web.archive.org/web/20201011084814/https://www.ina-registry.org/index.php?act=registry_trial_detail&code_trial=16202009080721WXFM0YX%2F|archive-date=October 11, 2020|access-date=August 15, 2020|url-status=live}}</ref> dan mendapatkan persetujuan untuk penggunaan darurat yang saat ini berlangsung di [[Brasil]], [[Chili]], [[Indonesia]], dan [[Turki]]. CoronaVac menggunakan teknologi serupa, tetapi lebih tradisional, dibandingkan dengan [[BBIBP-CorV]] dan [[BBV152]], vaksin virus inaktif COVID-19 lainnya yang juga sedang dalam uji coba tahap III.<ref>{{Cite news|date=2020-06-10|title=Coronavirus Vaccine Tracker|url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html|work=The New York Times|language=en-US|issn=0362-4331|access-date=2020-12-27}}</ref>
[[Brasil]] mengumumkan tingkat efikasi CoronaVac sebesar 50,38% pada 12 Januari 2021 berdasarkan data lengkap dari uji coba pada 12.508 peserta; tingkat efikasi ini hampir 30% lebih rendah dari hasil yang diumumkan sebelumnya dan hampir tidak cukup untuk mendapatkan persetujuan dari WHO dan Brasil.<ref>{{Cite web|title=Vacina CoronaVac tem eficácia global de 50,38% nos testes feitos no Brasil, diz Instituto Butantan|url=https://g1.globo.com/sp/sao-paulo/noticia/2021/01/12/vacina-coronavac-tem-eficacia-global-de-504percent-nos-testes-feitos-no-brasil-diz-instituto-butantan.ghtml|website=G1|language=pt-br|access-date=2021-01-12}}</ref><ref name="bloo_HowE">{{Cite web|last=Hong|first=Jinshan|date=January 12, 2021|title=How Effective Is China's Sinovac Vaccine? Data Confuse Experts|url=https://www.bloomberg.com/news/articles/2021-01-12/china-vaccine-going-global-with-four-different-efficacy-rates|access-date=January 12, 2021|agency=[[Bloomberg News]]}}</ref><ref name="wsj._Chin">{{Cite web|last=Pearson|first=Samantha|last2=Magalhaes|first2=Luciana|date=12 January 2021|title=Chinese Covid-19 Vaccine Is Far Less Effective Than Initially Touted in Brazil|url=https://www.wsj.com/articles/chinas-sinovac-covid-19-vaccine-is-50-4-in-late-stage-brazil-trials-11610470581|access-date=12 January 2021|newspaper=[[The Wall Street Journal]]}}</ref> [[Instituto Butantan]], penyelenggara uji coba, mengatakan angka yang lebih rendah disebabkan oleh standar penghitungan infeksi yang lebih ketat dibandingkan dengan pembuat vaksin lainnya.<ref name=":6">{{Cite web|title=Why did the efficacy of China’s top vaccine drop from 78% to 50%?|url=https://fortune.com/2021/01/13/sinovac-vaccine-efficacy-rate-drop/|website=Fortune|language=en|access-date=2021-01-14}}</ref> Sebelumnya, pada 7 Januari 2021, Instituto Butantan mengumumkan bahwa vaksin ini 78% efektif pada kasus ringan dan 100% efektif melawan infeksi berat dan sedang berdasarkan 220 kasus COVID-19 dari 13.000 sukarelawan tanpa merinci bagaimana tingkat efikasinya dihitung.<ref name=":2">{{Cite news|date=2021-01-07|title=Sinovac’s Covid Shot Proves 78% Effective in Brazil Trial|url=https://www.bloomberg.com/news/articles/2021-01-07/sinovac-covid-shot-78-effective-in-brazil-trial-folha-reports|work=Bloomberg.com|language=en|access-date=2021-01-07}}</ref>
[[Turki]] sebelumnya telah mengumumkan tingkat efikasi sebesar 91,25% dari analisis sementara terhadap 29 kasus yang didasarkan pada data dari 1.322 peserta dalam uji coba dengan 7.371 sukarelawan,<ref name="reut_Piec">{{Cite web|last=Staff|first=Reuters|date=December 28, 2020|title=Piecemeal data releases threaten to undermine Sinovac's COVID-19 vaccine|url=https://www.reuters.com/article/health-coronavirus-sinovac/piecemeal-data-releases-threaten-to-undermine-sinovacs-covid-19-vaccine-idINKBN2920RT|access-date=January 11, 2021|agency=[[Reuters]]}}</ref><ref name="nyti_Turk">{{Cite web|last=Zimmer|first=Carl|last2=Londoño|first2=Ernesto|date=December 25, 2020|title=Turkey and Brazil Say Chinese Vaccine Effective, With Sparse Supporting Data|url=https://www.nytimes.com/2020/12/25/health/turkey-brazil-sinovac-coronavirus-vaccine.html|access-date=January 11, 2021|newspaper=[[The New York Times]]}}</ref><ref name=":0">{{Cite web|title=Turkish official says CoronaVac vaccine 91.25% effective|url=https://abcnews.go.com/Health/wireStory/turkish-official-coronavac-vaccine-9125-effective-74899577|website=ABC News|language=en|access-date=2020-12-26}}</ref><ref name=":8">{{Cite web|date=December 25, 2020|title=Turkey set to receive 'effective' COVID-19 vaccine amid calls for inoculation|url=https://www.dailysabah.com/turkey/turkey-set-to-receive-effective-covid-19-vaccine-amid-calls-for-inoculation/news|website=Daily Sabah|language=en|access-date=December 26, 2020}}</ref> sementara Indonesia mengumumkan tingkat efikasi sebesar 65,3% berdasarkan data dari 1.600 peserta dalam uji coba mereka.<ref name=":5">{{Cite web|last=hermesauto|date=2021-01-11|title=Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy|url=https://www.straitstimes.com/asia/se-asia/indonesia-grants-emergency-use-approval-to-sinovac-vaccine-local-trials-show-65|website=The Straits Times|language=en|access-date=2021-01-11}}</ref>
|
